ProteinQure Collaborates with AstraZeneca to Design Novel Peptide Therapeutics
ProteinQure, a leader in computational protein drug discovery, announces a collaboration with the global biopharmaceutical company AstraZeneca to apply structure-based design to the creation of therapeutic libraries with the aim of accelerating the research and development of peptide therapeutics.
Peptide therapeutics have unique properties that make them highly effective against some disease targets outside the scope of traditional small molecule and antibody modalities. However, due to the number of peptide variations, very few of these potential therapeutics have been studied. Integrating high-accuracy biophysical models and machine learning, it is possible to explore this vast therapeutic space and design peptide libraries with broad applicability in drug discovery.
The collaboration will leverage ProteinQure's expertise in computational methods and structure-based drug design. AstraZeneca will conduct experimental validation, drawing on the company’s extensive expertise in biologics.
"We are excited to collaborate with AstraZeneca to demonstrate the application of our technology on a large scale. By combining ProteinQure's proprietary computational tools with AstraZeneca’s ability to refine and validate millions of therapeutic candidates in high-throughput, we can rapidly determine therapeutic leads outside the scope of conventional synthetic antibody libraries. State-of-the-art computational tools have not been fully explored in biologics R&D and we are excited to partner with AstraZeneca with the aim of discovering novel therapeutic leads for some of the most challenging drug targets faced by the industry," said Chris Ing, CSO, ProteinQure.
"The combination of designed peptide libraries, based on ProteinQure’s computational methods, with our advanced capabilities in display technologies will help us harness the potential of this therapeutic class. AstraZeneca continues to collaborate with cutting-edge companies in our ambition to discover novel treatments and increase the speed at which we can bring treatments to patients," said Tristan Vaughan, Vice President Antibody Discovery & Protein Engineering, R&D, AstraZeneca.
About ProteinQure Inc.
ProteinQure is a computational drug discovery platform for protein-based pharmaceuticals. Their platform combines quantum computing, machine learning and molecular dynamics simulations to help refine and optimize protein therapeutics. These techniques are less reliant on data than other computational approaches and have the potential to explore new therapeutic space. ProteinQure collaborates with its partners to help design the drugs of tomorrow. ProteinQure is headquartered in Toronto, Canada. For more information please visit www.proteinqure.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LIVE-IT-LTD4.8.2020 13:05:13 CEST | Press release
LIVE IT LTD and SSTC Inc Join Forces to Increase Venue Capacity During COVID
MA-ABIOMED4.8.2020 13:02:13 CEST | Press release
FDA Issues Emergency Use Authorization for Impella Heart Pumps to Provide Unloading Therapy to COVID-19 Patients
CA-VISA-INC.4.8.2020 09:03:45 CEST | Press release
Global Visa Study Finds 67% of Small Businesses and 78% of Consumers Have Adopted New Behaviors to Adjust to COVID-19
SMITHS-DETECTION4.8.2020 09:02:13 CEST | Press release
Smiths Detection Completes Acquisition of PathSensors
JDE-PEET’S4.8.2020 07:02:10 CEST | Press release
JDE Peet’s Reports Strong Half-year 2020 Results
PA-RELIEF-THERAPEUTICS3.8.2020 19:05:04 CEST | Press release
RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom